Akari Therapeutics Plc (AKTX) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001541157 · SEC filings checked Oct 17, 2026
Next report
Nov 13, 2026
Estimated from reporting history (92-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$8.18
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$0.00
Sum of quarters ending Jun 30, 2026, Mar 31, 2026, Dec 31, 2025, Sep 30, 2025
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 13, 2026 | — | $-4.8M | $0.00 | Filing |
| Mar 31, 2026 | May 19, 2026 | — | $-14.5M | $0.00 | Filing |
| Dec 31, 2025 | Mar 30, 2026 | — | $-5.3M | $0.00 | Filing |
| Sep 30, 2025 | Nov 13, 2025 | — | $-6.4M | $0.00 | Filing |
| Jun 30, 2025 | Aug 13, 2025 | — | $-1.9M | $0.00 | Filing |
| Mar 31, 2025 | Apr 16, 2025 | — | $-3.7M | $0.00 | Filing |
| Dec 31, 2024 | Apr 15, 2025 | — | $-3.8M | $0.00 | Filing |
| Sep 30, 2024 | Nov 19, 2024 | — | $-2.9M | $0.00 | Filing |
What would Akari Therapeutics Plc have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.